MediWound Ltd. Stock News

YAVNE, Israel, March 02, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (“Mediwound”), a biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, b

YAVNE, Israel, March 01, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair an

MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Research Project Award is for the Development of NexoBrid as a Non-Surgical Solution for Field Care Research Project Award is for the Development of NexoBrid as a Non-Surgical Solution for Field Care

YAVNE, Israel, Feb. 14, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and

YAVNE, Israel, Feb. 14, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD ), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that management would present at two upcoming investor conferences in February. Details for each is as follows: BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference Date: Wednesday, February 16, 2022 Time: 8:30 am ET Format: Fireside Chat Registration Link: Click here Aegis Virtual Investor Conference Date: Thursday, February 24, 2022 Time: 3:00 pm ET Link: Aegis Virtual Conference Calendar A replay of the fireside chat and presentation will be … Full story available on Benzinga.com

YAVNE, Israel, Feb. 14, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and r

The Biomedical Advanced Research and Development Authority (BARDA) will provide supplemental funding of $9 million to MediWound Ltd (NASDAQ: MDWD ) to Support NexoBrid application resubmission and the expanded access treatment protocol. The Company continues to advance the preparation of the FDA Marketing application resubmission anticipated in mid-2022. MediWound was awarded its first BARDA contract to treat thermal burn injuries in 2015. That … Full story available on Benzinga.com

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Announces Publication Of Positive Late-Stage Data For Keytruda-Chemo Combo In Breast Cancer Merc

MediWound (MDWD) is trading ~7% higher in the pre-market on Thursday after announcing that the Biomedical Advanced Research and Development Authority ((BARDA)) provided the company with

Primary Endpoint Met with Highly Statistically Significant ResultsNo Observed Safety IssuesFinal Data Readout Expected in Second Quarter of 2022

MediWound Ltd (NASDAQ: MDWD) has posted topline results from its U.S. Phase 2 study of EscharEx for the debridement (removal of dead or infected skin tissue for wound healing) of venous leg ulcers

In a phase two study, EscharEx demonstrated safe and effective debridement of diabetic foot ulcers and venous leg ulcers.

Wall Street analysts expect MediWound Ltd. (NASDAQ:MDWD) to report $5.65 million in sales for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for MediWounds earnings. The lowest sales estimate is $5.60 million and the highest is $5.70 million. MediWound reported sales of $6.67 million during the same quarter last year, which []

Analysts predict that MediWound Ltd. (NASDAQ:MDWD) will announce earnings per share of ($0.16) for the current quarter, Zacks reports. Two analysts have made estimates for MediWound’s earnings, with the highest EPS estimate coming in at ($0.14) and the lowest estimate coming in at ($0.17). MediWound reported earnings per share of ($0.06) during the same quarter […]